AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 172 min read$KMTS

Webster Brian Daniel sold $337K of KMTS

Webster Brian Daniel (See Remarks) sold 15,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $22.44 ($22.01–$24.00, $0.34M total) across 3 trades on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Jul 17, 2026, 9:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan; there is no new company fundamental catalyst in the text.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 designation typically limits interpretive value.

03

What to watch

The filing does not state whether additional insider sales occurred around the same period, nor does it provide post-sale performance or any new operational catalyst.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-17 for a 2026-07-15 insider sale.

Background

This is an SEC Form 4 insider transaction for Kestera Medical Technologies, Ltd. (KMTS) by an officer/director.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Insider Webster Brian Daniel sold $336,609 of KMTS shares via an open-market sale under a pre-arranged 10b5-1 plan on 2026-07-15.

Expected impact

Likely limited near-term impact; any reaction should be muted because the sale is pre-arranged and the article provides no new fundamentals.

Evidence & confidence

Form 4 shows a scheduled open-market sale (Code S) with a stated 10b5-1 plan, and no accompanying company-specific news (earnings, guidance, contracts, litigation) is included.

Market effects

Sector

No sector read-through; this is a single-company insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so traders may ignore it.

Key entities

  • issuer
    KMTS

    Kestra Medical Technologies, Ltd., the company whose insider transaction is disclosed.

  • insider
    Webster Brian Daniel

    Officer and director who sold shares under an open-market sale (10b5-1 plan).

Read at source← All news

Related articles

JUL 16
$KMTSMedAI 8/10

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.

yahoo.com6 min
JUL 15
$KMTSMed

Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue

Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.

yahoo.com4 min
JUL 15
$KMTSMed

Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript

Kestra Medical (KMTS) discussed its FY26 results on an earnings call. Revenue was $95 million for the year, up 59% from FY25, and $28.6 million in Q4, up 66% year over year. Gross margin rose to 51.4% for FY26 (up about 11 pts). The company reported 6.3k prescriptions and expanding sales territories to about 130.

yahoo.com7 min
JUL 14
$KMTSMedAI 8/10

Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies (Nasdaq: KMTS) announced a five-year, non-dilutive term loan facility managed by Pharmakon Advisors. It includes $75M funded at closing (used to retire a $45M loan plus fees), $25M available through July 2027, $50M through June 2028 subject to $150M trailing revenue, and a $50M acquisition tranche. Interest is SOFR plus 5.5% with a 3.25% floor; Kestra reported $262M cash/investments as of Apr. 30, 2026.

manilatimes.net4 min